ERK1/2 phosphorylation: a biomarker analysis within a phase I study with the new Raf kinase inhibitor BAY43-9006.

International journal of clinical pharmacology and therapeutics

Volumn 40, Issue 12, 2002, Pages 567-568

  Hilger, R A ^a   Kredke, S ^a   Hedley, D ^a   Moeller, J G ^a   Bauer, R J ^a   Stellberg, W ^a   Seeber, S ^a   Scheulen, M E ^a   Strumberg, D ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENZENESULFONIC ACID DERIVATIVE; BIOLOGICAL MARKER; ENZYME INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PYRIDINE DERIVATIVE; RAF PROTEIN; SORAFENIB;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG ANTAGONISM; HUMAN; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHOSPHORYLATION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; BENZENESULFONATES; BIOLOGICAL MARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; HUMANS; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-RAF; PYRIDINES;

EID: 1342271451     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP40567     Document Type: Article

References (0)